Applying cancer entity specific antigens on CTCs was meanwhile achieved by taking advantage of hepatocyte markers as Glypican3 and ASGPR1, in combination with EpCAM utilizing flow cytometry for experimental purpose 72, 81. Here, EPCAM is linked to cancer.